Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.

Despite promising results with FLT3 inhibitors (FLT3i), response durations remain short. We studied pretreatment and relapse bone marrow samples from patients with

Déclaration de conflit d'intérêts

Conflict of interest: MY reports research funding from Pfizer and Daiichi Sankyo. TK reports personal fees from Novartis, grants and personal fees from Pfizer, grants from BMS, grants and personal fees from Abbvie, grants and personal fees from Genentech, grants and personal fees from JAZZ, grants from Amgen, grants from AstraZeneca; Celgene: research grant; Incyte: research grant; Ascentage: research grant. CD reports grants and personal fees from Abbvie, grants and personal fees from Agios, grants and personal fees from Novartis, grants and personal fees from ImmuneOnc, grants and personal fees from Daiichi Sankyo, grants and personal fees from Celgene, personal fees from Jazz, personal fees from Notable Labs, personal fees from MedImmune, grants from Calithera, personal fees from Bayer. MK reports grants and other from AbbVie, grants and other from Genentech, grants and other from F. Hoffman La-Roche, grants and other from Stemline Therapeutics, other from Amgen, grants and other from Forty-Seven, other from Kisoji, grants from Eli Lilly, grants from Cellectis, grants from Calithera, grants from Ablynx, grants from Agios, grants from Ascentage, grants from Astra Zeneca, other from Reata Pharmaceutical, grants from Rafael Pharmaceutical, grants from Sanofi, outside the submitted work; In addition, Dr. Konopleva has a patent US 7,795,305 B2 CDDO-compounds and combination therapie with royalties paid to Reata Pharm., a patent Combination Therapy with a mutant IDH1 Inhibitor and a BCL-2 licensed to Eli Lilly, and a patent 62/993,166 combination of a MCL-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof pending to novartis. NP reports personal fees from Pacylex Pharmaceuticals, grants and other from Affymetrix, grants from SagerStrong Foundation, personal fees from Incyte, personal fees and other from Novartis, personal fees from LFB Biotechnologies, personal fees, non-financial support and other from Stemline Therapeutics, personal fees and non-financial support from Celgene, personal fees, non-financial support and other from AbbVie, personal fees and non-financial support from MustangBio, personal fees from Roche Diagnostics, personal fees from Blueprint Medicines, personal fees and non-financial support from DAVA Oncology, other from Samus Therapeutics, other from Cellectis, other from Daiichi Sankyo, other from Plexxikon. EJ reports research grants and consultancy from Abbvie, Adaptive biotechnology, Amgen, BMS, Pfizer, Takeda. NS reports personal fees from Amgen, personal fees from AstraZeneca, grants and personal fees from Takeda, grants from Astellas. GI reports grants and personal fees from Novartis, grants from Syndax, grants from Celgene. FR reports honoraria and member of advisory board from Astellas, honoraria from Daichii, honoraria and member of advisory board from Novartis. ND reports research funding from Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Karyopharm, Sevier, Genentech, Astellas, Abbvie, Genentech, Novimmune, Amgen, Trovagene, Gilead and ImmunoGen and has served in a consulting or advisory role for Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Novartis, Celgene, AbbVie, Genentech, Servier, Trillium, Syndax, Trovagene, Astellas, Gilead and Agios.